Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Share-based Compensation (2023 - 2025)

Mangoceuticals' Share-based Compensation history spans 3 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 207.07% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.3 million, up 99.87%, while the annual FY2024 figure was $248682.0, 60.18% down from the prior year.
  • Share-based Compensation for Q3 2025 was $1.1 million at Mangoceuticals, up from $50979.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.1 million in Q3 2025 and bottomed at -$1.0 million in Q3 2024.
  • The 3-year median for Share-based Compensation is $64271.0 (2023), against an average of $188626.9.
  • The largest YoY upside for Share-based Compensation was 1109.42% in 2024 against a maximum downside of 1698.23% in 2024.
  • A 3-year view of Share-based Compensation shows it stood at $429079.0 in 2023, then tumbled by 88.12% to $50979.0 in 2024, then skyrocketed by 2057.35% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Share-based Compensation are $1.1 million (Q3 2025), $50979.0 (Q2 2025), and $50979.0 (Q1 2025).